<DOC>
	<DOCNO>NCT00101764</DOCNO>
	<brief_summary>The use intravitreal injection corticosteroid ( triamcinolone acetonide ) appear promising treatment variety ocular disease associate inflammation . To date , drug available , `` Kenalog-40 Injection '' produce Bristol Myers Squibb , formulate intraocular use . The purpose study evaluate long-term safety potential efficacy novel intravitreal injection preservative-free formulation triamcinolone acetonide ( TAC-PF ) two dosage level ( 4 mg 8 mg ) compare anterior sub-tenon injection TAC-PF 20 mg . The study mask , randomized Phase I study enroll 120 participant one follow disease : age-related macular degeneration ( AMD ) , diabetic macular edema ( DME ) , central retinal vein occlusion ( CRVO ) , branch retinal vein occlusion ( BRVO ) , retinal disease associate macular edema . At least 21 participant enrol four designated disease stratum : AMD , DME , CRVO , BRVO . The remain 36 participant may one disease may enrol another retinal disease . Within disease stratum , least seven participant randomized dose group . The participant randomly assign one three treatment group . The primary outcome assessment post-injection intraocular toxicity-related event 3-year follow-up , include cataract formation , development glaucoma , adverse event prevent retreatment . The secondary outcome improvement best-corrected visual acuity ( BCVA , EVA ) decrease retinal thicken area leakage , baseline year 1 .</brief_summary>
	<brief_title>Intravitreal v. Sub-tenon Injections Triamcinolone Acetonide Macular Edema Retinal Disorders</brief_title>
	<detailed_description>The use intravitreal injection corticosteroid ( triamcinolone acetonide ) appear promising treatment variety ocular disease associate inflammation . To date , drug available , `` Kenalog-40 Injection '' produce Bristol Myers Squibb , formulate intraocular use . The purpose study evaluate long-term safety potential efficacy novel intravitreal injection preservative-free formulation triamcinolone acetonide ( TAC-PF ) two dosage level ( 4 mg 8 mg ) compare anterior sub-tenon injection TAC-PF 20 mg . The study mask , randomized Phase I study enroll 120 participant one follow disease : age-related macular degeneration ( AMD ) , diabetic macular edema ( DME ) , central retinal vein occlusion ( CRVO ) , branch retinal vein occlusion ( BRVO ) , retinal disease associate macular edema . At least 21 participant enrol four designated disease stratum : AMD , DME , CRVO , BRVO . The remain 36 participant may one disease may enrol another retinal disease . Within disease stratum , least seven participant randomized dose group . The participant randomly assign one three treatment group . Depending participant 's response , injection may repeat 3-month interval . Participants follow last enrolled participant complete 3 year follow-up . The primary outcome assessment post-injection intraocular toxicity-related event 3-year follow-up , include cataract formation , development glaucoma , adverse event prevent retreatment . The secondary outcome improvement best-corrected visual acuity ( BCVA ) decrease retinal thicken area leakage , baseline year 1 .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>INCLUSION CRITERIA : All Participants must : 1 . Understand sign inform consent . 2 . Be least 18 year age . 3 . Have definite retinal thickening due macular edema study eye , base clinical exam . 4 . Have retinal thickness great equal 250 micron central subfield OCT. 5 . Have BCVA equal worse 20/40 study eye . 6 . Have sufficiently clear ocular medium permit good quality retinal photograph angiography allow assessment macular area accord standard clinical practice . 7 . Be able comply study requirement . EXCLUSION CRITERIA : All participant must : Have intraocular pressure great 25 history suggest glaucoma ( e.g. , history diagnosis glaucoma , disc/nerve fiber layer defect suggestive glaucoma ) glaucomatous visual field defect document Goldmann Humphrey perimetry take within 6 month qualification . 2 . Be allergic fluorescein dye . 3 . Have medical condition make consistent followup treatment period unlikely ( e.g. , stroke , severe MI , endstage cancer , history chronic renal failure require dialysis kidney transplant ) . 4 . Have blood pressure great 180/110 . 5 . Be currently use likely need systemic ocular medication know toxic lens , retina , optic nerve , : 1 . Deferoxamine 2 . Chloroquine/Hydroxychloroquine ( Plaquenil ) 3 . Tamoxifen 4 . Phenothiazines 5 . Ethambutol 6 . Have use experimental therapy present disease past 3 month . 7 . Have contraindication perform necessary diagnostic procedure . 8 . Have history current acute ocular periocular infection ( include history ocular herpes zoster simplex ) . 9 . Have major intraocular surgical procedure within one month enrollment . 10 . Have use systemic steroid excess average 20 mg daily dose past 3 month . 11 . Have know history untoward complication corticosteroid therapy , include elevate intraocular pressure response topical periocular corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 20, 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>CRVO</keyword>
	<keyword>BRVO</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Age-Related Macular Degeneration ( AMD )</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>Branch Retinal Vein Occlusion</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>Retinal Disorder</keyword>
</DOC>